We are live on ! Find out more
VPHM

VIROPHARMA INC
VPHM

Delisted

VPHM was delisted on the 23rd of January, 2014.

172 hedge funds and large institutions have $3.29B invested in VIROPHARMA INC in 2013 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 47 increasing their positions, 61 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more funds holding in top 10

Funds holding in top 10: 411 (+7)

14% more capital invested

Capital invested by funds: $2.87B → $3.29B (+$416M)

10% less funds holding

Funds holding: 191172 (-19)

23% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 61

25% less first-time investments, than exits

New positions opened: 52 | Existing positions closed: 69

57% less call options, than puts

Call options by funds: $67.1M | Put options by funds: $155M

Holders
172
Holders Change
-19
Holders Change %
-9.95%
% of All Funds
4.99%
Holding in Top 10
11
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+175%
% of All Funds
0.32%
New
52
Increased
47
Reduced
61
Closed
69
Calls
$67.1M
Puts
$155M
Net Calls
-$87.5M
Net Calls Change
-$82.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Citadel Advisors
176
Citadel Advisors
Florida
-$57.4M -1,284,579 -100%
MC
177
Maverick Capital
Texas
-$49.1M -1,250,175 Closed
AIMCA
178
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
-$32.3M -822,608 Closed
FAM
179
Fred Alger Management
New York
-$31M -789,469 Closed
WCM Investment Management
180
WCM Investment Management
California
-$26M -662,263 Closed
SAM
181
Sectoral Asset Management
Quebec, Canada
-$21.8M -556,024 Closed
PCM
182
Penn Capital Management
Pennsylvania
-$21.4M -544,858 Closed
Alkeon Capital Management
183
Alkeon Capital Management
New York
-$19.6M -500,000 Closed
AC
184
Apex Capital
California
-$13.7M -350,000 Closed
TCM
185
Tamarack Capital Management
California
-$13.7M -350,000 Closed
MCM
186
Munder Capital Management
Michigan
-$13.5M -342,835 Closed
EA
187
Emerald Advisers
Pennsylvania
-$9.22M -234,960 Closed
TCM
188
Tygh Capital Management
Oregon
-$7.93M -202,048 Closed
CIP
189
Chartwell Investment Partners
Pennsylvania
-$7.34M -187,004 Closed
PAMU
190
Pictet Asset Management (UK)
United Kingdom
-$7.32M -186,300 Closed
MAA
191
Managed Account Advisors
New Jersey
-$6.85M -174,496 Closed
Arrowstreet Capital
192
Arrowstreet Capital
Massachusetts
-$6.11M -155,535 Closed
Hudson Bay Capital Management
193
Hudson Bay Capital Management
Connecticut
-$5.97M -151,800 Closed
Wellington Management Group
194
Wellington Management Group
Massachusetts
-$5.81M -147,900 Closed
Axa
195
Axa
France
-$5.48M -139,391 Closed
FWIA
196
Fort Washington Investment Advisors
Ohio
-$5.25M -133,805 Closed
LOAMU
197
Lombard Odier Asset Management (USA)
New York
-$4.13M -105,000 Closed
CIM
198
Calvert Investment Management
Maryland
-$4.12M -104,867 Closed
SFM
199
Soros Fund Management
New York
-$3.93M -100,000 Closed
MWP
200
MYCIO Wealth Partners
Pennsylvania
-$3.9M -99,265 Closed

VPHM Hedge Fund Activity: Q4 2013 in Review

172 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in VIROPHARMA INC (VPHM) for Q4 2013, worth a combined $3.29B — up 14% from $2.87B a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of VPHM and 52 opened new positions — a net loss of 17 holders — while 61 trimmed existing stakes and 47 added.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $137M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $220M sold.

  • 172 institutional investors held VIROPHARMA INC (VPHM) as of Q4 2013, down from 191 in Q3 2013.
  • Funds reported $3.29B of VIROPHARMA INC stock for Q4 2013, up 14% quarter-over-quarter.
  • 52 funds opened new VIROPHARMA INC positions in Q4 2013 and 69 closed out, a net change of -17 holders.
  • The largest VIROPHARMA INC buyer in Q4 2013 was Oxford Asset Management, an estimated $137M added.
  • The largest VIROPHARMA INC seller in Q4 2013 was Baker Bros. Advisors, an estimated $220M sold.

Based on aggregated 13F filings for Q4 2013.